The use of an anti-CD3 immunotoxin to prevent the development of lymphoproliferative disease in SCID/PBL mice

Journal of Immunological Methods

Volumn 218, Issue 1-2, 1998, Pages 141-153

  Clinchy, Birgitta ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

CD3; Immunotoxin; Lymphoproliferative disease; SCID PBL

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY CD3; RICIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINED IMMUNODEFICIENCY; CYTOTOXICITY; DEGLYCOSYLATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR DIAGNOSIS; XENOGRAFT;

ANIMALS; ANTIGENS, CD3; FEMALE; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOGLOBULINS; IMMUNOTOXINS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICE; MICE, SCID; RICIN; T-LYMPHOCYTES; TUMOR VIRUS INFECTIONS;

ANIMALIA; HUMAN HERPESVIRUS 4;

EID: 0032170351     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(98)00123-9     Document Type: Article

References (47)

1. Bosma G.C., Fried M., Custer R.P., Carroll A., Gibson D.M., Bosma M.J. Evidence of functional lymphocytes in some (leaky) SCID mice. J. Exp. Med. 167:1988;1016.
2. Boyle T.J., Tamburini M., Berend K.R., Kizilbash A.M., Borowitz M.J., Lyerly H.K. Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. Surgery. 112:1992;378.
3. Brinkmann U., Pastan I. Immunotoxins against cancer. Biochim. Biophys. Acta. 1198:1994;27.
4. Campana D., Janossy G., Bofill M., Trejdosiewicz L.K., Ma D., Hoffbrand A.V., Mason D.Y., LeBacq A.-M., Forster H.K. Human B cell development: I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J. Immunol. 134:1985;1524.
5. Cannon M.J., Pisa P., Fox R.I., Cooper N.R. Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J. Clin. Invest. 85:1990;1333.
6. Carlsson R., Martensson C., Kalliomaki S., Ohlin M., Borrebaeck C.A.K. Human peripheral blood lymphocytes transplanted into SCID mice constitute an in vivo culture system exhibiting several parameters found in a normal humoral immune response and are a source of immunocytes for the production of human monoclonal antibodies. J. Immunol. 148:1992;1065.
7. Coles R.E., Boyle T.J., DiMaio J.M., Berend K.R., Via D.F., Lyerly H.K. T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. Ann. Surg. Oncol. 1:1994;405.
8. Duchosal M.A., Eming S.A., McConahey P.J., Dixon F.J. The hu-PBL-SCID mouse model. Cell. Immunol. 139:1992;468.
9. Ellenhorn J.D.I., Woodle E.S., Ghobreal I., Thistlethwaite J.R., Bluestone J.A. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation. 50:1990;608.
10. Fulton R.J., Tucker T.F., Vitetta E.S., Uhr J.W. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: Effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization. Cancer Res. 48:1988;2618.
11. Fulton R.J., Uhr J.W., Vitetta E.S. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins. J. Immunol. 136:1986;3103.
12. Ghetie M.A., Richardson J., Tucker T., Jones D., Uhr J.W., Vitetta E.S. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int. J. Cancer. 45:1990;481.
13. Ghetie M.A., Richardson J., Tucker T., Jones D., Uhr J.W., Vitetta E.S. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphomas grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res. 51:1991;5876.
14. Ghetie M.A., Tucker K., Richardson J., Uhr J.W., Vitetta E.S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood. 80:1992;2315.
15. Hansen, J.A., Martin, P.J., Beatty, P.G., Clark, E.A., Ledbetter, J.A., 1984. Human T lymphocyte cell surface molecules defined by the workshop monoclonal antibodies ('T cell protocol'). In: Bernard, A., Boumsell, L., Dausset, J., Milstein, C., Schlossman, S.F. (Eds.), Leukocyte Typing: Human Leukocyte Markers Detected by Monoclonal Antibodies, Springer, New York, p. 195.
16. Hesselton R.M., Koup R.A., Cromwell M.A., Graham B.S., Johns M., Sullivan J.L. Human peripheral blood xenografts in the SCID mouse: Characterization of immunologic reconstitution. J. Infect. Dis. 168:1993;630.
17. Hirsch R., Gress R.E., Pluznik D.H., Eckhaus M., Bluestone J.A. Effects on in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice: II. In Vivo Activation of T Cell. J. Immunol. 142:1989;737.
18. Hoffmann-Fezer G., Kranz B., Gall C., Thierfelder S. Peritoneal sanctuary for human lymphopoiesis in SCID mice injected with human peripheral blood lymphocytes from Epstein-Barr virus-negative donors. Eur. J. Immunol. 22:1992;3161.
19. Itoh T., Shiota M., Takanashi M., Hojo I., Satoh H., Matsuzawa A., Moriyama T., Watanabe T., Hirai K., Mori S. Engraftment of human non-Hodgkin lymphomas in mice with severe combined immunodeficiency. Cancer. 72:1993;2686.
20. Kapp U., Wolf J., Hummel M., Pawlita M., von Kalle C., Dallenbach F., Schwonzen M., Krueger G.R.F., Müller-Lantzsch N., Fonatsch C., Stein H., Diehl V. Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice. Blood. 82:1993;1247.
21. Klein E., Klein G., Nadkarni J.S., Nadkarni J.J., Wigzell H., Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 28:1968;1300.
22. Leo O., Foo M., Sachs D.H., Samelson L.E., Bluestone J.A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA. 84:1987;1374.
23. Martin P.J., Hansen J.A., Torok-Storb B., Moretti L., Press O., Storb R., Thomas E.D., Weiden P.L., Vitetta E.S. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant. 3:1988;437.
24. Martin P.J., Hansen J.A., Vitetta E.S. A ricin A chain-containing immunotoxin that kills human T lymphocytes in vitro. Blood. 66:1985;908.
25. Martin P.J., Shulman H.M., Schubach W.H., Hansen J.A., Fefer A., Miller G., Thomas E.D. Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann. Intern. Med. 101:1984;310.
26. Mosier D.E., Gulizia R.J., Baird S.M., Wilson D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 335:1988;256.
27. Murphy W.J., Conlon K.C., Sayers T.J., Wiltrout R.H., Back T.C., Ortaldo J.R., Longo D.L. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency. J. Immunol. 150:1993;3634.
28. Nakamine H., Masih A.S., Okano M., Taguchi Y., Pirruccello S.J., Davis J.R., Mahloch M.L., Beisel K.W., Kleveland K., Sanger W.G., Purtilo D.T. Characterization of clonality of Epstein-Barr virus-induced human B lymphoproliferative disease in mice with severe combined immunodeficiency. Am. J. Pathol. 142:1993;139.
29. Neville D.M., Scharff J., Srinivasachar K. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. Proc. Natl. Acad. Sci. U.S.A. 89:1992;2585.
30. Neville D.M., Scharff J., Hu H.Z., Rigaut K., Shiloach J., Slingerland W., Jonker M. A new reagent for the induction of T-Cell depletion, Anti-CD3-CRM9. J. Immunother. 19:1996;85.
31. Okano M., Taguchi Y., Nakamine H., Pirruccello S.J., Davis J.R., Beisel K.W., Kleveland K.L., Sanger W.G., Fordyce R.R., Purtilo D.T. Characterization of Epstein-Barr virus-induced lymphoproliferation derived from human peripheral blood mononuclear cells transferred to severe combined immunodeficient mice. Am. J. Pathol. 137:1990;517.
32. Olsnes, S., Pihl, A., 1982. Toxic lectins and related proteins. In: Cohen, P., van Heyningen, S. (Eds.), Molecular Action of Toxins and Viruses, Elsevier, New York, p. 51.
33. Read R.J., Stein P.E. Toxins. Curr. Opin. Struct. Biol. 3:1993;853.
34. Rowe M., Young L.S., Crocker J., Stokes H., Henderson S., Rickinson A.B. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J. Exp. Med. 173:1991;147.
35. Simpson E., Farrant J., Chandler P. Phenotypic and functional studies of human peripheral blood lymphocytes engrafted in scid mice. Immunol. Rev. 124:1991;97.
36. Street N.E., Fulton R.J., Sanders V.M., Vitetta E.S. Inhibition of the helper function of murine T cells with Fab'-anti-L3T4 ricin A chain immunotoxin. J. Immunol. 139:1987;1734.
37. Swinnen L.J., Constanzo-Nordin M.R., Fisher S.G., O'Sullivan E.J., Johnson M.R., Dizikes G.J., Pifarre R., Fisher R.I. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N. Engl. J. Med. 323:1990;1723.
38. Tax W.M., Willems H.W., Reekers P.P.M., capel P.J.A., Koene R.A.P. Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature. 304:1983;445.
39. Thorpe P.E., Detre S.I., Foxwell B.M.J., Brown A.N.F., Skilleter D.N., Wilson G., Forrester J.A., Stirpe F. Modification of the carbohydrate in ricin with metaperiodate - cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur. J. Biochem. 147:1985;197.
40. Thrush G.R., Lark L.R., Clinchy B.C., Vitetta E.S. Immunotoxins: an update. Annu. Rev. Immunol. 14:1996;49.
41. Torbett B.E., Picchio G., Mosier D.E. hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis. Immunol. Rev. 124:1991;139.
42. Vallera D.A., Carroll S.F., Brief S., Blazar B.R. Anti-CD3 immunotoxin prevents low-dose STZ/interferon-induced autoimmune diabetes in mouse. Diabetes. 41:1992;457.
43. Vallera D.A., Taylor P.A., Panoskaltsis-Mortair A., Blazar B.R. Therapy of ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab') 2-ricin toxin A chain immunotoxin. Blood. 86:1995;4367.
44. Van Wauwe J.P., De Mey J.R., Goossens J.G. OKT3: a monclonal anti-human T lymphocyte antibody with potent mitogenic properites. J. Immunol. 124:1980;2708.
45. Veronese M.L., Veronesi A., D'Andrea E., Del Mistro A., Indraccolo S., Mazza M.R., Mion M., Zamarchi R., Menin C., Panozzo M., Amadori A., Chieco-Bianchi L. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice: I. T lymphocyte requirement for B-cell tumor generation. J. Exp. Med. 176:1992;1763.
46. Waller E.K., Kamel O.W., Cleary M.L., Majumdar A.S., Schick M.R., Lieberman M., Weissman I.L. Growth of primary T-cell non-Hodgkin's lymphomata in SCID-hu mice: requirement for a human lymphoid microenvironment. Blood. 78:1991;2650.
47. Weiss A., Wiskocil R.L., Stobo J.D. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J. Immunol. 133:1984;123.